STOCK TITAN
  1. Home
  2. Sec-filings
  3. PRCT
  4. [8-K] PROCEPT BioRobotics Corp Reports Material Event

PROCEPT BioRobotics (Nasdaq: PRCT) grows Q1 2026 revenue 20% but stays loss-making

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

PROCEPT BioRobotics reported strong top-line growth but continued losses for the quarter ended March 31, 2026. Revenue rose 20% year over year to $83.1 million, driven by higher U.S. system and handpiece sales and 25% growth in international revenue. Gross margin improved to 65%, up from 64% a year ago and 61% in the prior quarter.

U.S. Aquablation procedures reached about 12,200, up roughly 30% year over year, and the U.S. install base grew to 765 systems, a 40% increase. Despite this growth, operating expenses increased to $86.6 million, leading to a net loss of $31.6 million and Adjusted EBITDA loss of $18.1 million. The company ended the quarter with about $249 million in cash and reaffirmed 2026 guidance, including revenue of $390–$410 million and an Adjusted EBITDA loss of $30–$17 million. PROCEPT also highlighted recent FDA clearance of its second-generation FirstAssist AI software, further enhancing its HYDROS robotic system.

Positive

  • None.

Negative

  • None.

Insights

Fast revenue and procedure growth continue, but losses remain sizable.

PROCEPT BioRobotics delivered Q1 2026 revenue of $83.1M, up 20% year over year, with U.S. revenue at $72.0M and international revenue at $11.1M. U.S. procedures grew about 30% to roughly 12,200, and the U.S. install base reached 765 systems, up 40%.

Profitability is still a challenge. Operating expenses increased to $86.6M from $71.6M, driving a net loss of $31.6M and Adjusted EBITDA loss of $18.1M. Guidance for 2026 remains for revenue of $390M–$410M, gross margin around 65%, and Adjusted EBITDA loss of $30M–$17M, implying ongoing investment-heavy growth.

Liquidity appears solid with $249M in cash, cash equivalents and restricted cash at March 31, 2026. The recent FDA clearance of second-generation FirstAssist AI software may support future adoption of the HYDROS robotic system, though the financial impact is not quantified in these results.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Q1 2026 Revenue $83.1M Three months ended March 31, 2026; up 20% year over year
Q1 2026 Gross Margin 65% Three months ended March 31, 2026; 64% in prior-year period
Q1 2026 Net Loss $31.6M Three months ended March 31, 2026; compared to $24.7M loss in 2025
Q1 2026 Adjusted EBITDA ($18.1M) Three months ended March 31, 2026; Adjusted EBITDA loss
Cash, cash equivalents and restricted cash $249M Balance at March 31, 2026
U.S. procedures 12,200 Approximate U.S. Aquablation procedures in Q1 2026; ~30% YoY growth
U.S. install base 765 systems Ending U.S. HYDROS install base at March 31, 2026; 40% YoY increase
2026 Revenue Guidance $390M–$410M Full-year 2026 revenue outlook; 27%–33% growth vs prior year
Adjusted EBITDA financial
"Adjusted EBITDA* was a loss of $18.1 million for the first quarter of 2026"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
gross margin financial
"Gross margin of approximately 65% for the first quarter of 2026, compared to 64% in the prior year period"
Gross margin is the difference between how much money a company makes from selling its products and how much it costs to produce them, expressed as a percentage of sales. It shows how efficiently a company is turning sales into profit before other expenses like marketing or salaries. Higher gross margin means the company keeps more money from each sale, which is a good sign of financial health.
FirstAssist AI technical
"recently received FDA clearance of its second-generation FirstAssist AI™ software, an advancement in personalized, image-guided planning"
FirstAssist AI is an artificial intelligence-powered assistant designed to help frontline staff and managers perform routine tasks faster—things like answering questions, triaging issues, summarizing information, or suggesting next steps. For investors, it matters because such tools can lower operating costs, speed service delivery, and scale a company's capacity without hiring as many people, while also bringing potential issues around data privacy, accuracy, and regulatory oversight that can affect value.
Aquablation therapy medical
"The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy."
A minimally invasive procedure that uses a doctor-guided, high‑velocity waterjet controlled by imaging and robotic guidance to remove excess prostate tissue causing urinary obstruction. Think of it like a precision pressure washer that cuts away problem tissue while preserving surrounding structures. Investors watch aquablation because its clinical outcomes, procedure time, complication rates, and reimbursement prospects influence demand for the devices and services that enable the treatment.
benign prostatic hyperplasia medical
"to enable personalized, precise, and durable treatment for the millions of men affected by benign prostatic hyperplasia (BPH)."
Benign prostatic hyperplasia is a noncancerous enlargement of the prostate gland that can squeeze the urethra and cause urinary symptoms like weak stream, urgency, and incomplete emptying; think of it as a garden hose being pinched so water flow slows. It matters to investors because it creates steady demand for medications, medical devices and procedures, regulatory approvals, and insurance coverage decisions—factors that can drive revenue and growth in healthcare companies serving an aging population.
non-GAAP financial measures financial
"This press release references Adjusted EBITDA, a financial measure that is not prepared in accordance with generally accepted accounting principles"
Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.
Revenue $83.1M +20% YoY
Gross margin 65% from 64% prior-year; 61% in Q4 2025
Net loss $31.6M vs $24.7M loss prior-year
Adjusted EBITDA ($18.1M) vs ($15.8M) prior-year
U.S. procedures 12,200 approx. +30% YoY
Guidance

For full-year 2026, revenue is expected at $390M–$410M (27%–33% growth), gross margin around 65%, and Adjusted EBITDA loss between $30M and $17M.

Understanding 8-K Material Events →
0001588978false00015889782026-04-292026-04-29

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 29, 2026
PROCEPT BIOROBOTICS CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 001-40797 26-0199180
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification Number)
150 Baytech Drive
San Jose, California 95134
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (650) 232-7200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Common Stock, $0.00001 par value per share PRCT The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company   ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐


Item 2.02 Results of Operations and Financial Condition
On April 29, 2026, PROCEPT BioRobotics Corporation (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.
Exhibit No.Description
99.1
Press Release of PROCEPT BioRobotics Corporation, dated April 29, 2026
104Cover Page Interactive Data File, formatted in Inline XBRL.


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PROCEPT BIOROBOTICS CORPORATION
Date: April 29, 2026
By:
/s/ Alaleh Nouri
Alaleh Nouri
Chief Legal Officer and Secretary



PROCEPT BioRobotics Reports First Quarter 2026 Financial Results

SAN JOSE, Calif., April 29, 2026 -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2026.
"Over the past six months, we have taken decisive actions to reset the organization by sharpening our focus on operational excellence, accountability, and commercial discipline, and our first quarter results reflect the early impact of that work," said Larry Wood, Chief Executive Officer. "We delivered $83.1 million in revenue, driven by strong U.S. system sales and improved pricing."

Wood continued: “Aquablation® users completed approximately 12,200 U.S. procedures in the first quarter of 2026. Handpiece sales were about 95% of procedures, reflecting normalizing field inventory levels. While our recent commercial realignment created some near-term disruption, the team is adapting quickly, and we expect the benefits to build through the year, driving sustained growth and improved profitability.”

First Quarter 2026 Financial Results
•Total revenue of $83.1 million for the first quarter of 2026, an increase of 20% compared to the prior year period in 2025
•U.S. procedures of approximately 12,200 for the first quarter of 2026, an increase of approximately 30% compared to the prior year period
•Sold 49 U.S. Hydros® systems, which included 2 replacement systems. U.S. average selling prices were approximately $485,000 for new Hydros systems
•U.S. handpieces sold as percent of U.S. procedures in the first quarter of 2026 was approximately 95%
•First quarter of 2026 handpiece average selling price of approximately $3,500 increased 5% compared to the fourth quarter of 2025
•March 31, 2026 ending U.S. install base of 765 systems, representing a 40% increase compared to the prior year period
•International revenue of $11.1 million for the first quarter of 2026, an increase of 25% compared to the prior year period
•Gross margin of approximately 65% for the first quarter of 2026, compared to 64% in the prior year period and 61% in the fourth quarter of 2025

Total revenue for the first quarter of 2026 was $83.1 million, an increase of 20% compared to the prior year period. The increase was driven by increased U.S. handpiece and system revenue and international revenue. U.S. revenue was $72.0 million, representing growth of 19% compared to the prior year period. U.S. handpiece and consumable revenue for the first quarter of 2026 was $43.0 million, an increase of 13% compared to the prior year period. U.S. system revenue for the first quarter of 2026 was $23.4 million, an increase of 25% compared to the prior year period. International revenue was $11.1 million for the quarter, an increase of 25% compared to the prior year period.

Gross margin for the first quarter of 2026 was 65% compared to 64% in the prior year period. Gross margin increase in the first quarter was primarily driven by revenue mix and pricing, offset by inventory cost capitalization and increased tariff expense compared to the prior year period.

Operating expenses in the first quarter of 2026 were $86.6 million, compared with $71.6 million in the prior year period. The increase in operating expenses reflects continued investment to support commercial expansion, innovation across our BPH platform technology and increased funding for our WATER IV Prostate Cancer trial.

Net loss was $31.6 million for the first quarter of 2026, compared to a loss of $24.7 million in the prior year period. Adjusted EBITDA* was a loss of $18.1 million for the first quarter of 2026, compared to a loss of $15.8 million in the prior year period.

Cash, cash equivalents and restricted cash balances as of March 31, 2026, totaled approximately $249 million.

The Company also recently received FDA clearance of its second-generation FirstAssist AI™ software, an advancement in personalized, image-guided planning for Aquablation therapy. This milestone further strengthens the capabilities of the HYDROS robotic system, the Company’s next-generation AI-powered platform. The enhanced software enables more precise identification of prostate anatomy and more complete treatment planning to help surgeons plan with greater confidence and consistency.

The Company remains committed to advancing the standard of care in urology through continued innovation, combining AI, robotics, and real-time imaging to enable personalized, precise, and durable treatment for the millions of men affected by benign prostatic hyperplasia (BPH).



Full Year 2026 Financial Guidance
•The Company continues to expect revenue for the full year 2026 to be in the range of $390 million to $410 million, which represents growth of 27% to 33% compared to the prior year period
•The Company continues to expect full year 2026 U.S. procedure growth to be in the range of 39% to 48% compared to the prior year period
•The Company continues to expect full year 2026 gross margin to be approximately 65%
•The Company continues to expect full year 2026 adjusted EBITDA* loss to be in the range of $30 million to $17 million

*Adjusted EBITDA is a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States (GAAP). For more information about the Company’s use of non-GAAP financial measures, please see the section below titled “Use of Non-GAAP Financial Measures (Unaudited).

Webcast and Conference Call Information
PROCEPT BioRobotics will host a conference call to discuss the first quarter 2026 financial results on Wednesday, April 29, 2026, at 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by following one of the links below:
•Webcast link for interested listeners:
◦https://edge.media-server.com/mmc/p/rdtftqik/
•Dial-in registration for sell-side research analysts:
◦https://register-conf.media-server.com/register/BIac4b002880274c7086f519f21b93cd1f

About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with approximately 250 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Use of Non-GAAP Financial Measures (Unaudited)
This press release references Adjusted EBITDA, a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States (GAAP). The Company defines Adjusted EBITDA as earnings before interest expense, taxes, depreciation and amortization and stock-based compensation. Non-GAAP financial measures are not a substitute for or superior to measures of financial performance prepared in accordance with GAAP and should not be considered as an alternative to any other performance measures derived in accordance with GAAP.
The Company believes that presenting Adjusted EBITDA provides useful supplemental information to investors about the Company in understanding and evaluating its operating results, enhancing the overall understanding of its past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by its management in financial and operational decision making. However, there are a number of limitations related to the use of non-GAAP measures and their nearest GAAP equivalents. For example, other companies may calculate non-GAAP measures differently, or may use other measures to calculate their financial performance, and therefore any non-GAAP measures the Company uses may not be directly comparable to similarly titled measures of other companies.
Forward Looking Statements
This release contains forward‐looking statements within the meaning of federal securities laws, including with respect to the Company’s projected financial performance for full year 2026, statements regarding the potential utilities, values, benefits and advantages of Aquablation therapy performed using PROCEPT BioRobotics’ products, including AquaBeam or Hydros Robotic Systems, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on the Company’s current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which the Company is not currently aware. Forward-looking statements may include statements regarding financial guidance, market opportunity and penetration, procedure growth, the Company’s possible or assumed future results of operations, including descriptions of the Company’s revenues, gross margins, profitability, operating expenses, installed base growth, commercial momentum and overall business strategy. Forward‐looking statements should not be read as a guarantee of future performance or results and may not


necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. These forward‐looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward‐looking statements as a result of these risks and uncertainties. These risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the Company’s annual report on Form 10-K filed with the SEC on February 26, 2026, and subsequent quarterly reports on Form 10-Q. PROCEPT BioRobotics does not undertake any obligation to update forward‐looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward‐looking statements contained herein. These forward-looking statements should not be relied upon as representing PROCEPT BioRobotics’ views as of any date subsequent to the date of this press release.
Important Safety Information
All surgical treatments have inherent and associated side effects. For a list of potential side effects visit https://aquablation.com/safety-information/

Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
m.bacso@procept-biorobotics.com















PROCEPT BioRobotics Corporation
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, in thousands, except per share data)
Three Months Ended March 31,
2026
2025
Revenue
$
83,132 
$
69,162 
Cost of sales
29,185 
25,001 
Gross profit
53,947 
44,161 
Operating expenses:
Research and development
21,465 
16,402 
Selling, general and administrative
65,088 
55,197 
Total operating expenses
86,553 
71,599 
Loss from operations
(32,606)
(27,438)
Interest expense
(818)
(877)
Interest and other income, net
1,743 
3,531 
Loss before income taxes
(31,681)
(24,784)
Provision for income taxes
(43)
(47)
Net loss
$
(31,638)
$
(24,737)
Net loss per share, basic and diluted
$
(0.56)
$
(0.45)
Weighted-average common shares used to
Compute net loss per share attributable to
Common shareholders, basic and diluted
56,511 
54,917 


PROCEPT BioRobotics Corporation
RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA
(Unaudited, in thousands)

Three Months Ended March 31,
2026
2025
Net loss
$
(31,638)
$
(24,737)
Depreciation and amortization expense
1,735 
1,475 
Stock-based compensation expense
13,072 
10,108 
Interest (income) and interest expense, net
(1,291)
(2,654)
Adjusted EBITDA
$
(18,122)
$
(15,808)

















PROCEPT BioRobotics Corporation
RECONCILIATION OF GAAP NET LOSS TO ADJUSTED 2026 EBITDA Guidance
(Unaudited, in thousands)

For the Year Ending December 31, 2026
LOW
HIGH
Net loss
$
(91,500)
$
(78,500)
Depreciation and amortization expense
7,500 
7,500 
Stock-based compensation expense
59,000 
59,000 
Interest (income) and interest expense, net
(5,000)
(5,000)
Adjusted EBITDA
$
(30,000)
$
(17,000)













































PROCEPT BioRobotics Corporation
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, in thousands)

March 31, 2026
December 31, 2025
Assets
Current assets:
Cash and cash equivalents
$
245,641 
$
286,503 
Accounts receivable, net
96,388 
83,533 
Inventory
77,536 
70,694 
Prepaid expenses and other current assets
8,469 
9,648 
Total current assets
428,034 
450,378 
Restricted cash, non-current
3,038 
3,038 
Property and equipment, net
31,739 
30,399 
Operating lease right-of-use assets, net
17,162 
17,538 
Intangible assets, net
640 
709 
Other assets
6,449 
6,019 
Total assets
$
487,062 
$
508,081 
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable
$
18,851 
$
17,285 
Accrued compensation
18,476 
23,175 
Deferred revenue
13,702 
13,048 
Operating leases, current
2,358 
2,214 
Other current liabilities
10,249 
10,073 
Total current liabilities
63,636 
65,795 
Long-term debt
51,664 
51,615 
Operating leases, non-current
23,974 
24,654 
Other non-current liabilities
121 
147 
Total liabilities
139,395 
142,211 
Stockholders’ equity:
Additional paid-in capital
1,020,881 
1,007,390 
Accumulated other comprehensive gain
(19)
37 
Accumulated deficit
(673,195)
(641,557)
Total stockholders’ equity
347,667 
365,870 
Total liabilities and stockholders’ equity
$
487,062 
$
508,081 



















PROCEPT BioRobotics Corporation
REVENUE BY TYPE AND GEOGRAPHY
(Unaudited, in thousands)

Three Months Ended March 31,
2026
2025
U.S.
System sales and rentals
$
23,386 
$
18,687 
Handpieces and other consumables
43,018 
38,011 
Service
5,614 
3,596 
Total U.S. revenue
72,018 
60,294 
Outside of U.S.
System sales and rentals
3,853 
3,853 
Handpieces and other consumables
6,372 
4,477 
Service
889 
538 
Total outside of U.S. revenue
11,114 
8,868 
Total revenue
$
83,132 
$
69,162 





































PROCEPT BioRobotics Corporation
QUARTERLY U.S. INSTALL BASE AND PROCEDURES
(Unaudited, in thousands)



Q1'24
Q2'24
Q3'24
Q4'24
Q1'25
Q2'25
Q3'25
Q4'25
Q1'26
Q2'26
Q3'26
Q4'26
FY 24
FY 25
FY 26
U.S. Install Base
Beginning install base
315 
354
400
445
505
547
595
653
718
315
505
Systems placed
39 
46 
45 
60 
42 
48 
58 
65 
47 
190 
213 
Ending install base
354 
400 
445 
505 
547 
595 
653 
718 
765 
— 
— 
— 
505 
718 
U.S Procedures (000)
6.1 
7.0 
7.4 
7.2 
9.3 
10.8 
11.0 
12.2 
12.2 

Source: View Original Filing on SEC EDGAR

FAQ

How did PROCEPT BioRobotics (PRCT) perform financially in Q1 2026?

PROCEPT BioRobotics reported Q1 2026 revenue of $83.1 million, up 20% year over year. U.S. revenue reached $72.0 million and international revenue was $11.1 million. Despite growth, the company posted a net loss of $31.6 million and an Adjusted EBITDA loss of $18.1 million.

Did PROCEPT BioRobotics maintain its full-year 2026 guidance?

Yes. PROCEPT BioRobotics continues to expect 2026 revenue of $390–$410 million, implying 27%–33% year-over-year growth. The company also guides to full-year gross margin of about 65% and an Adjusted EBITDA loss between $30 million and $17 million for 2026.

What is PROCEPT BioRobotics’ profitability profile in Q1 2026?

The company remains unprofitable, reporting a Q1 2026 net loss of $31.6 million versus $24.7 million a year earlier. Operating expenses rose to $86.6 million, and Adjusted EBITDA was a loss of $18.1 million. Higher spending reflects commercial expansion, platform innovation, and funding of the WATER IV trial.

How strong is PROCEPT BioRobotics’ balance sheet after Q1 2026?

At March 31, 2026, PROCEPT BioRobotics held about $249 million in cash, cash equivalents and restricted cash. Total assets were $487.1 million and total liabilities were $139.4 million, resulting in stockholders’ equity of $347.7 million, supporting ongoing investment in growth initiatives.

What new technology updates did PROCEPT BioRobotics announce with Q1 2026 results?

The company recently received FDA clearance of its second-generation FirstAssist AI software. This software enhances personalized, image-guided planning for Aquablation therapy and strengthens the capabilities of the HYDROS robotic system, aiming to improve anatomical identification and treatment planning consistency for surgeons.

What are PROCEPT BioRobotics’ key revenue components in Q1 2026?

In Q1 2026, U.S. system sales and rentals generated $23.4 million, U.S. handpieces and consumables $43.0 million, and U.S. service revenue $5.6 million. Outside the U.S., system, consumable, and service revenue totaled $11.1 million, bringing total revenue to $83.1 million.

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents